Discovery of a Potent 9-Deazaxanthine-based Agent for the Treatment of Obesity-Related Non-alcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Discovery of a Potent 9-Deazaxanthine-based Agent for the Treatment of Obesity-Related Non-alcoholic Fatty Liver Disease

Published:2015-05-14 Issue:1 Volume:86 Page:66-79
ISSN:1747-0277
Container-title:Chemical Biology & Drug Design
language:en
Short-container-title:Chem Biol Drug Des

Author:

Chen Jinying¹²,Ma Liang¹,Huang Li²,Xie Caifeng²,Pei Heying²,He Linhong²,Fu Suhong²,Chen Lijuan²

Affiliation:

1. Division of Nephrology; Kidney Research Institute; West China Hospital; Sichuan University; Chengdu 610041 China

2. State Key Laboratory of Biotherapy and Cancer Center; West China Hospital; Sichuan University, and Collaborative Innovation Center for Biotherapy; Chengdu 610041 China

Funder

National Key Programs of China

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cbdd.12429/fullpdf

Reference24 articles.

1. Treatment of non-alcoholic fatty liver disease;Adams;Postgrad Med J,2006

2. Nonalcoholic fatty liver disease;Angulo;Engl J Med,2002

3. Non-alcoholic fatty liver disease: current concepts and management strategies;Day;Clin Med,2006

4. Non-alcoholic fatty liver disease and the metabolic syndrome;Marchesini;Curr Opin Lipidol,2005

5. Histological assessment of non-alcoholic fatty liver disease;Hübscher;Histopathology,2006

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation;RSC Advances;2016